SHANGHAI HEARTCARE MEDICAL TECHNOLOGY CORPORATION LIMITED Shanghai HeartCare Medical Technology Corporation Limited Share Price
Equities
6609
CNE100004MN5
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.9 HKD | -3.87% |
|
+8.22% | -39.83% |
| Sales 2024 * | 342M 47.27M 370M 3.77B | Sales 2025 * | 462M 63.78M 499M 5.09B | Capitalization | 657M 90.72M 710M 7.23B |
|---|---|---|---|---|---|
| Net income 2024 * | 1M 138K 1.08M 11.01M | Net income 2025 * | 37M 5.11M 39.97M 407M | EV / Sales 2024 * | 0.54 x |
| Net cash position 2024 * | 473M 65.34M 511M 5.21B | Net cash position 2025 * | 364M 50.32M 394M 4.01B | EV / Sales 2025 * | 0.63 x |
| P/E ratio 2024 * |
861
x | P/E ratio 2025 * |
17.9
x | Employees | 368 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.14% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.87% | ||
| 1 week | +8.22% | ||
| Current month | -7.73% | ||
| 1 month | -10.41% | ||
| 3 months | -13.32% | ||
| 6 months | -33.33% | ||
| Current year | -39.83% |
1 week
16.02
18.74
1 month
15.6420.30
Current year
15.6427.50
1 year
15.6443.00
3 years
15.64147.50
5 years
15.64147.50
10 years
15.64147.50
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Hui Wang
CEO | Chief Executive Officer | 46 | 15/06/16 |
Zongyu Xue
CHM | Chairman | 39 | 31/10/17 |
Han Zhang
DFI | Director of Finance/CFO | 36 | 22/11/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shao Mu Guo
BRD | Director/Board Member | 58 | 22/11/20 |
Kui Ding
FOU | Founder | 42 | 15/06/16 |
Gang Chen
BRD | Director/Board Member | 40 | 30/06/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 17.9 | -3.87% | 500 |
| 29/04/24 | 18.62 | +3.91% | 5,000 |
| 26/04/24 | 17.92 | +5.04% | 104,650 |
| 25/04/24 | 17.06 | +2.90% | 88,100 |
| 24/04/24 | 16.58 | +0.24% | 116,500 |
Delayed Quote Hong Kong S.E., April 30, 2024 at 09:08 am
More quotes
Shanghai HeartCare Medical Technology Corp Ltd is a China-based company engaged in the research and development of innovative neuro-interventional medical device. The Company's product portfolio includes both neuro-interventional and cardiac medical devices, and its main products are CaptorTM thrombectomy device (Captor) and left atrial appendage occluder. The Company's product portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis to the treatment of hemorrhagic stroke. The Company's other products include the balloon guiding catheter, the ExtraFlex distal access catheter and SupSelek microcatheter. The Company distributes its products within the domestic market.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.22
CNY
Average target price
27.12
CNY
Spread / Average Target
+57.44%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.83% | 90.74M | |
| -2.54% | 186B | |
| -1.85% | 107B | |
| -4.26% | 67.44B | |
| +1.39% | 50.03B | |
| +16.82% | 47.81B | |
| +4.79% | 41.03B | |
| +3.49% | 26.85B | |
| +0.65% | 25.82B | |
| +16.55% | 24.74B |
- Stock Market
- Equities
- 6609 Stock
